Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.
Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley E, Joseph I, Boccia A, Kelly R, Wortham K, Wang Q, Berquist L, Huang F, Gao SX, Zhang Y, Lugovskoy A, Martin S, Gouvis H, Berkowitz S, Chiang G, Reff M, Glaser SM, Hariharan K, Demarest SJ. Dong J, et al. Among authors: reff m. J Biol Chem. 2011 Feb 11;286(6):4703-17. doi: 10.1074/jbc.M110.184317. Epub 2010 Dec 1. J Biol Chem. 2011. PMID: 21123183 Free PMC article.
Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo.
Doern A, Cao X, Sereno A, Reyes CL, Altshuler A, Huang F, Hession C, Flavier A, Favis M, Tran H, Ailor E, Levesque M, Murphy T, Berquist L, Tamraz S, Snipas T, Garber E, Shestowsky WS, Rennard R, Graff CP, Wu X, Snyder W, Cole L, Gregson D, Shields M, Ho SN, Reff ME, Glaser SM, Dong J, Demarest SJ, Hariharan K. Doern A, et al. Among authors: reff me. J Biol Chem. 2009 Apr 10;284(15):10254-67. doi: 10.1074/jbc.M809709200. Epub 2009 Feb 11. J Biol Chem. 2009. PMID: 19211557 Free PMC article.
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, Boccia A, Virata C, Gamez J, Yco G, Favis M, Wu X, Graff CP, Wang Q, Rohde E, Rennard R, Berquist L, Huang F, Zhang Y, Gao SX, Ho SN, Demarest SJ, Reff ME, Hariharan K, Glaser SM. Dong J, et al. Among authors: reff me. MAbs. 2011 May-Jun;3(3):273-88. doi: 10.4161/mabs.3.3.15188. Epub 2011 May 1. MAbs. 2011. PMID: 21393993 Free PMC article.
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL. Lukashev M, et al. Among authors: reff m. Cancer Res. 2006 Oct 1;66(19):9617-24. doi: 10.1158/0008-5472.CAN-06-0217. Cancer Res. 2006. PMID: 17018619
Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L, Fan J, Chong JH, Cesena A, Tam BY, Gilson C, Boykin C, Wang D, Aivazian D, Marcotte D, Xiao G, Le Brazidec JY, Piao J, Lundgren K, Hong K, Vu K, Nguyen K, Gan LS, Silvian L, Ling L, Teng M, Reff M, Takeda N, Timple N, Wang Q, Morena R, Khan S, Zhao S, Li T, Lee WC, Taveras AG, Chao J. Zhang L, et al. Among authors: reff m. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5633-7. doi: 10.1016/j.bmcl.2011.06.129. Epub 2011 Jul 13. Bioorg Med Chem Lett. 2011. PMID: 21798738
Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D, Hanna N, Bugelski PJ, Brigham-Burke M, Crysler C, Gagnon RC, Dal Monte P, Doyle ML, Hensley PC, Reddy MP, Sweet RW, Truneh A. Newman R, et al. Among authors: reff m. Clin Immunol. 2001 Feb;98(2):164-74. doi: 10.1006/clim.2000.4975. Clin Immunol. 2001. PMID: 11161972
48 results